Search
Metoprolol
go.drugbank.com/drugs/DB00264ApprovedInvestigational[A175162] Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.[L5527]
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigationalAvatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby … Doptelet Sprinkle (avatrombopag oral granules), specifically designed for children aged one to less than six years, while the existing tablet formulation remains indicated for patients aged six years and older
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273848] In order to further reduce the risk of toxicities and improve efficacy, penpulimab was designed with Fc mutations in order to eliminate Fc receptor and complement-mediated effector function, … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalA propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and p...
Cysteamine
go.drugbank.com/drugs/DB00847ApprovedInvestigational[L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines
Insulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigationalA18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight … [A18561,A18562,A18563,A18564,A174934] Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Avanafil
go.drugbank.com/drugs/DB06237ApprovedIn comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively